Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.
Miguel Villalona-Calero, MD
Advertisement
Articles by Miguel Villalona-Calero, MD
Miguel Villalona-Calero, MD, discusses the unique mechanism of action of the CDK9 inhibitor KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid TumorsPublished: November 9th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer
2
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
3
Zavabresib Nets FDA Orphan Drug Designation for Myelofibrosis
4
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
5